Department of Gastroenterology, Peking Union Medical College Hospital, Peking Union Medical College, Chinese Academy of Medical Sciences, Beijing 100730, PR China.
Oncol Rep. 2012 Jul;28(1):303-10. doi: 10.3892/or.2012.1794. Epub 2012 Apr 30.
Previous studies have shown that S100P contributes to the development of a number of tumors. However, its prognostic significance in colorectal cancer (CRC) has not been demonstrated. This study aimed to confirm the expression of S100P in colorectal cancer as well as the epigenetic mechanism underlying its gene expression, and to demonstrate whether S100P could be used to predict prognosis as a biomarker. We tested the expression of S100P in 96 CRCs and their paired tissue controls, as well as 13 colon cancer cell lines by RT-PCR and western blotting. Expression of the S100P protein and mRNA was significantly higher in cancerous regions compared to that in paired non-cancerous tissues (P=4.59 x 10(-17), 0.005 respectively). The expression was significantly correlated with the hypomethylation of the S100P promoter (P=4.92 x 10(-5)), which was detected by bisulphite sequencing PCR (BSP) and quantitative methylation-specific real-time PCR (QMSP). In stages I to III, the patients with positive expression of S100P protein showed poorer overall survival compared to those with S100P negative expression, P=0.031. We also measured the preoperative serum S100P levels by ELISA. The patients with normal serum levels of S100P showed favorable prognosis compared with patients with elevated S100P levels (P=0.008). These data suggest that S100P protein may be a potential novel prognostic biomarker in CRC patients.
先前的研究表明，S100P 有助于多种肿瘤的发展。然而，其在结直肠癌（CRC）中的预后意义尚未得到证实。本研究旨在确认 S100P 在结直肠癌中的表达以及其基因表达的表观遗传机制，并证明 S100P 是否可以作为生物标志物用于预测预后。我们通过 RT-PCR 和 Western blot 检测了 96 例 CRC 及其配对组织对照以及 13 种结肠癌细胞系中 S100P 的表达。与配对的非癌组织相比，癌组织中 S100P 蛋白和 mRNA 的表达明显升高（P=4.59 x 10(-17)，0.005）。表达与 S100P 启动子的低甲基化显著相关（P=4.92 x 10(-5)），通过亚硫酸氢盐测序 PCR（BSP）和定量甲基化特异性实时 PCR（QMSP）检测到了这一点。在 I 期至 III 期，S100P 蛋白阳性表达的患者总生存率明显低于 S100P 阴性表达的患者，P=0.031。我们还通过 ELISA 测量了术前血清 S100P 水平。与 S100P 水平升高的患者相比，S100P 血清水平正常的患者预后较好（P=0.008）。这些数据表明，S100P 蛋白可能是 CRC 患者潜在的新型预后生物标志物。
